-7%
Zycortal Suspension / Desoxycorticosterone Pivalate Injection) Canine Endocrine Therapeutics: The Definitive Guide to Mineralocorticoid Pharmacology, Electrolyte Homeostasis, and Clinical Management
Managing canine primary hypoadrenocorticism (Addison’s Disease), severe electrolyte imbalances, hyponatremia, hyperkalemia, circulatory collapse, and life-threatening hypovolemic shock in canine patients requires a precision-formulated, long-acting mineralocorticoid replacement therapy that restores normal renal electrolyte handling without inducing glucocorticoid excess. When dogs suffer from adrenal cortex atrophy, inadequate aldosterone production, profound sodium wasting, and dangerous potassium retention, targeted parenteral hormonal intervention is essential to replenish essential mineralocorticoids, normalize serum electrolyte ratios, and sustain normal blood pressure and hydration.
Left unmanaged, canine Addisonian crises lead to severe cardiac arrhythmias, profound bradycardia, vascular collapse, renal failure, and fatal cardiovascular shock.
Relying solely on acute fluid resuscitation or short-acting oral steroids frequently fails to maintain stable, long-term electrolyte homeostasis or prevent recurring crisis episodes.
To provide targeted, life-sustaining endocrine support backed by veterinary clinical standards, modern veterinary endocrinology relies on gold-standard sustained-release mineralocorticoid injectables. Zycortal ($25\ \text{mg/mL}$, $4\ \text{mL}$ Vial Format / Desoxycorticosterone Pivalate Injection) is a premier, professional-grade parenteral suspension formulated to deliver controlled, prolonged release of desoxycorticosterone pivalate ($\text{DOCP}$), engineered to regulate sodium and potassium balance in dogs suffering from hypoadrenocorticism.
Endocrine Pharmacology & Electrolyte Regulation Kinetics
Zycortal delivers a targeted biochemical mechanism engineered to restore renal electrolyte reabsorption and systemic fluid balance:
[Zycortal 25 mg/mL Suspension Administered Subcutaneously Every 25-30 Days]
|
[Slow, Controlled Systemic Release of Desoxycorticosterone Pivalate (DOCP)]
|
[Binding to Mineralocorticoid Receptors in Distal Renal Tubules]
|
-------------------------------------------------
| |
[ENHANCEMENT OF SODIUM REABSORPTION] [ENHANCEMENT OF POTASSIUM EXCRETION]
(Retains Sodium and Chloride in Bloodstream) (Promotes Renal Potassium Elimination in Urine)
| |
v v
[RESTORATION OF FLUID VOLUME] [NORMALIZATION OF SODIUM-TO-POTASSIUM RATIO]
(Expands Intravascular Blood Volume) (Corrects Dangerous Hyperkalemia & Hyponatremia)
| |
v v
[Prevention of Addisonian Crises] [Stabilization of Cardiac Conduction]
(Maintains Normal Blood Pressure & Perfusion) (Eliminates Risk of Arrhythmias and Shock)
| |
=========================> <=====================
|
v
[Complete Endocrine Homeostasis and Electrolyte Balance]
|
[Sustained Normal Hydration, Stable Cardiac Function, & Peak Canine Vitality]
1. Mechanism of Action and Molecular Structure
Desoxycorticosterone Pivalate ($\text{DOCP}$) is a potent mineralocorticoid analog. It exerts its primary therapeutic effect by acting on the distal renal tubules of the kidneys, promoting the active reabsorption of sodium and chloride ions while stimulating the excretion of potassium and hydrogen ions. By restoring normal sodium and potassium balance (optimizing the $\text{Na:K}$ ratio), $\text{DOCP}$ expands extracellular fluid volume, stabilizes blood pressure, and reverses the metabolic abnormalities characteristic of Addison’s disease.
2. Pharmacokinetic Profile
Sustained Subcutaneous Release: Formulated as an oily microcrystalline suspension that dissolves slowly following subcutaneous injection, providing a steady, predictable release of active drug over a prolonged duration.
Extended Dosing Interval: Designed to maintain consistent therapeutic mineralocorticoid activity for approximately 25 to 30 days, minimizing the need for daily dosing.
Primary Clinical Indications
Zycortal $25\ \text{mg/mL}$ ($4\ \text{mL}$ Vial) is utilized across specialized canine veterinary clinical protocols for:
Treatment of Canine Primary Hypoadrenocorticism (Addison’s Disease): Long-term management and hormone replacement therapy for dogs suffering from inadequate endogenous mineralocorticoid secretion.
Electrolyte Stabilization: Correction and prevention of life-threatening hyperkalemia (elevated blood potassium) and hyponatremia (depleted blood sodium) associated with Addisonian states.
Recommended Administration and Dosing Protocols
To guarantee absolute precision, safe subcutaneous delivery, and individualized hormonal balance, Zycortal must be administered strictly under veterinary supervision with regular electrolyte monitoring.
Dosing Reference Table
The table below outlines standard operational parameters for Zycortal $25\ \text{mg/mL}$ ($4\ \text{mL}$ Vial):
| Parameter | Operational Specification |
| Vial Concentration | Sterile aqueous suspension containing $25\ \text{mg}$ of Desoxycorticosterone Pivalate per $1\ \text{mL}$ ($4\ \text{mL}$ total volume) |
| Initial Starting Dosage | $2.2\ \text{mg/kg}$ ($1.0\ \text{mg/lb}$) body weight administered subcutaneously every 25 days |
| Primary Administration Route | Subcutaneous ($\text{SC}$) injection |
| Target Species | Canine patients diagnosed with primary hypoadrenocorticism (Addison’s disease) |
Clinical Safety, Precautions, and Storage
Concurrent Glucocorticoid Requirement: Because Zycortal provides strictly mineralocorticoid activity, dogs with Addison’s disease typically require concurrent daily oral glucocorticoid supplementation (such as prednisone or prednisolone) to replace missing cortisol.
Monitoring Required: Regular monitoring of serum sodium, potassium, and clinical signs (such as lethargy, vomiting, or polyuria) is mandatory during initial dose titration and long-term maintenance.
Storage Parameters: Store at controlled room temperature between 15°C and 30°C (59°F and 86°F). Protect from freezing and shake well before each use. Once punctured, use within the designated shelf-life timeframe.
Frequently Asked Questions (FAQ)
What is the active ingredient in Zycortal?
Each milliliter contains Desoxycorticosterone Pivalate ($\text{DOCP}$) at $25\ \text{mg/mL}$, a long-acting mineralocorticoid hormone replacement.
How is Zycortal administered to dogs?
It is administered via subcutaneous ($\text{SC}$) injection, typically repeated every 25 to 30 days based on individual patient electrolyte monitoring.
Why do dogs with Addison’s disease need Zycortal?
Dogs with Addison’s disease lack natural aldosterone, leading to dangerous sodium loss and potassium buildup. Zycortal restores normal sodium-potassium balance, preventing fatal cardiac arrhythmias and shock.
Where can I buy genuine Zycortal for Dogs online?
You can safely source authentic, pharmaceutical-grade Zycortal ($25\ \text{mg/mL}$, $4\ \text{mL}$ Vial) online through Equines Vet Care. We store all specialized veterinary endocrine preparations under rigorous climate-controlled conditions to guarantee absolute product freshness, safety, and full potency.
Secure Professional Sourcing from Equines Vet Care
At Equines Vet Care, we understand that managing canine Addison’s disease, maintaining endocrine stability, and ensuring precise hormonal therapy require uncompromising product purity and strict quality control. Every unit of Zycortal ($25\ \text{mg/mL}$, $4\ \text{mL}$ Vial) is procured through authorized distribution networks, stored in our climate-controlled facility, and dispatched with precision.
Zycortal Suspension (desoxycorticosterone pivalate) is a critical medication for managing primary adrenocortical insufficiency, commonly known as Addison’s Disease, in dogs. This condition, or hypoadrenocorticism, results from inadequate function of the adrenal glands, which impairs essential bodily functions such as metabolism, blood pressure regulation, and stress response. Zycortal provides effective replacement therapy for the mineralocorticoid deficit by mimicking the natural hormone aldosterone.
Key Features:
Active Ingredient: 25 mg/ml desoxycorticosterone pivalate
Indication: Replacement therapy for mineralocorticoid deficiency in Addison’s Disease
Administration: Subcutaneous (SQ) injection
Dosage: 1 mg per pound of body weight every 25 days
Benefits of Zycortal Suspension for Dogs:
Enhanced Quality of Life: Improves overall well-being and comfort in dogs with Addison’s Disease
Electrolyte Balance: Normalizes sodium and potassium levels, addressing electrolyte imbalances
Increased Blood Volume: Expands extracellular fluid volume, enhancing blood volume and cardiac output
Prevents Complications: Reduces the risk of hypotensive shock and prerenal azotemia
How Zycortal Suspension Works:
Addison’s Disease affects the adrenal glands, disrupting hormone production necessary for regulating key bodily functions. Zycortal Suspension helps replace the missing mineralocorticoids, thereby restoring electrolyte balance and fluid volume. This helps manage symptoms and maintain stable blood pressure and overall health.
Important Considerations:
Not a Cure: Zycortal helps manage symptoms but does not cure Addison’s Disease
Glucocorticoid Therapy Required: Additional daily glucocorticoid treatment (e.g., prednisone or prednisolone) is necessary
Lifelong Treatment: Ongoing therapy with Zycortal and glucocorticoids is required for effective management
Administration Instructions:
Injection: Administer via subcutaneous (SQ) injection
Initial Dose: 1 mg per pound of body weight every 25 days
Follow Directions: Give exactly as prescribed by your veterinarian. Consult your veterinarian if you have any questions.
Zycortal Suspension offers crucial support for managing Addison’s Disease in dogs, helping to stabilize their condition and enhance their quality of life. Ensure regular administration and follow veterinary instructions for optimal results.
Reviews
There are no reviews yet.